Browsing Biomedical Research Center by Subject "Nanomedicine"
Now showing items 1-6 of 6
-
Effect of flow-induced shear stress in nanomaterial uptake by cells: Focus on targeted anti-cancer therapy
( MDPI , 2020 , Article)© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Recently, nanomedicines have gained a great deal of attention in diverse biomedical applications, including anti-cancer therapy. Being different from normal tissue, ... -
Halloysite nanotubes and halloysite-based composites for biomedical applications
( Elsevier , 2021 , Article)Novel biomaterials for diagnostics and therapeutics of biomedical issues have been considered using biomedical science and health care. Halloysite nanotubes (HNTs) are naturally occurring aluminosilicate clay. Because of ... -
Internalization of metal-organic framework nanoparticles in human vascular cells: Implications for cardiovascular disease therapy
( Multidisciplinary Digital Publishing Institute (MDPI) , 2020 , Article)Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide. Alteration of endothelial cells and the underlying vasculature plays a central role in the pathogenesis of various CVDs. The ... -
Nanomedicine for Cancer.
( Bentham Science Publishers , 2022 , Other)Over the past decades, oncology has occupied the lion’s share of all nanomedical applications [1-3]. In 2020, up to 65% of the clinical trials involving nanomaterials were attending to cancer therapeutics and diagnostics ... -
Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases
( MDPI , 2022 , Article)Cardiovascular diseases (CVDs) are the leading causes of morbidity and mortality worldwide. However, despite the recent developments in the management of CVDs, the early and long outcomes vary considerably in patients, ... -
Studies on metal–organic framework (MOF) nanomedicine preparations of sildenafil for the future treatment of pulmonary arterial hypertension
( nature , 2021 , Article)Pulmonary arterial hypertension (PAH) is an incurable disease, although symptoms are treated with a range of dilator drugs. Despite their clinical benefits, these drugs are limited by systemic side-effects. It is, therefore, ...